

Corp. Off.:- 201, "The Summit Business Bay" Behind Guru Nanak Petrol Pump, Off Andheri Kurla Road, Andheri (E), Mumbai - 400 093 (India) Ph. : +91 22 69073100



August 21, 2022

**BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <u>Scrip Code: 533543</u>

**The National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>Scrip code: BROOKS</u>

Dear Sirs,

## Sub: Update under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements, 2015) regarding approval for Meropenem Injection 500mg per vial and 1gram per vial (the product) from the United States Food & Drug Administration (USFDA)

We are pleased to update you that our subsidiary Brooks Steriscience Limited (BSL) has received approval for Meropenem Injection 500mg per vial and 1gram per vial (the product) from the United States Food & Drug Administration (USFDA). The product is generic equivalent to the Merrem® Injection of Pfizer Inc.

This approval from USFDA marks Brooks' foray into the US, which is the largest generic market in the World. Brooks manufactures its carbapenem range of injectables at its dedicated facility at Vadodara, India. The facility is approved by several regulatory agencies, including the European Union, and is equipped to produce a wide range of products meeting global quality standards.

Meropenem Injection is an intravenous beta-lactam antibiotic used to treat various bacterial infections. It is indicated for treating complicated skin and skin structure infections, intra-abdominal infections, and bacterial meningitis to reduce the development of drug-resistant bacteria and maintain the effectiveness of the injection and other antibacterial drugs.

According to IQVIA, Meropenem has an estimated market size of US\$ 78 million for the twelve months ending June 2022. In May 2022, BSL also received the marketing authorization for Meropenem injections in the United Kingdom and European Union. Global Penem market is US\$ 2.6 billion as on June 2022 as per IQVIA.

We request you to take the above on record.

Thanks & Regards,

For Brooks Laboratories Limited For Brooks Laboratories Ltd.



Authorised Signatory

Rajesh Mahajan Managing Director DIN No: 02000634

Regd. Off & Works : Village Kishanpura, Baddi Nalagarh Road, Baddi (H.P.) - 174101 (India) Tele Fax .: 01795 236939 (CIN NO: L24232HP2002PLC000267), E-mail : investors@brookslabs.net, Website: www.brookslabs.net